Beyond Air, Inc.

Equities

XAIR

US08862L1035

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.5666 ^USD	-5.25%		-3.97%	-71.09%

Jul. 09	Beyond Air, Inc. announced that it has received $0.128 million in funding	CI
Jul. 01	Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell 3000E Growth Index	CI

AIT Therapeutics, Inc. Announces the Appointment of Duncan Fatkin as Chief Commercial Officer

January 02, 2019 at 08:30 am EST

AIT Therapeutics, Inc. announced the appointment of Duncan Fatkin to the newly created position of Chief Commercial Officer. Mr. Fatkin will be responsible for leading the company's commercial activities.

Latest news about Beyond Air, Inc.

Beyond Air, Inc. announced that it has received $0.128 million in funding	Jul. 08	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell 3000E Growth Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell Microcap Value Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell 3000E Value Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell 2000 Value Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell 2000 Growth Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell 2500 Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell 3000 Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell 2000 Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell 3000 Value Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell 3000 Growth Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell 2500 Value Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell Small Cap Comp Growth Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell 2000 Dynamic Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell Small Cap Comp Value Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell Small Cap Completeness Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell 3000E Index	Jun. 30	CI
Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell 2500 Growth Index	Jun. 30	CI
Beyond Air, Inc. Enters into That Certain First Amendment to Loan Documents with Avenue Capital Management Ii, L.P., Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund Ii, L.P	Jun. 27	CI
Sector Update: Health Care Stocks Ease Late Afternoon	Jun. 25	MT
Sector Update: Health Care	Jun. 25	MT
Top Midday Decliners	Jun. 25	MT
Piper Sandler Cuts Price Target on Beyond Air to $3.50 From $7, Maintains Overweight Rating	Jun. 25	MT
BTIG Downgrades Beyond Air to Neutral From Buy	Jun. 25	MT
Beyond Air Share Plunge After Fiscal Q4 Loss Exceeds Estimates	Jun. 24	MT

Chart Beyond Air, Inc.

Duration

Period

More charts

Company Profile

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. It is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Its approved product and active pipeline of product candidates include LungFit PH, LungFit PRO and LungFit GO.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-07 - Q1 2025 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Beyond Air, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.5666 USD

Average target price

5.167 USD

Spread / Average Target

+811.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BEYOND AIR, INC.	-71.09%	26.01M
ABBOTT LABORATORIES	-5.31%	181B
MEDTRONIC PLC	-5.38%	99.95B
BECTON, DICKINSON AND COMPANY	-6.04%	66.21B
HOYA CORPORATION	+16.45%	45.4B
DEXCOM, INC.	-8.08%	45.36B
CENCORA, INC.	+8.38%	43.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+12.06%	29.03B
TERUMO CORPORATION	+17.98%	25.64B
WEST PHARMACEUTICAL SERVICES, INC.	-8.28%	23.53B

Other Medical Equipment, Supplies & Distribution